Companies /Healthcare

Adaptive Biotechnologies Corp

NASDAQ: ADPT Diagnostics & Research
$28.46
▼ $0.03 (−0.11%) today
Markets closed · 6:31am ET

ADPT at a Glance

Valuation
Market cap
$4.6B
Profitability
Revenue (TTM)
$298.0M
Profit margin
-23.7%
EPS (TTM)
$-0.45
Price
52-week range
$12 – $32
Street target
$32.57
Earnings
Next report
Feb 3, 2027

Headquartered in Seattle, WA Fiscal year ends December NASDAQ: ADPT adaptivebiotech.com

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company that decodes the genetics of the adaptive immune system to diagnose, monitor and treat disease. Its proprietary immune medicine platform sequences and interprets T-cell and B-cell receptor repertoires at scale. The company operates two segments.

The Minimal Residual Disease (MRD) segment is anchored by the clonoSEQ test, which detects residual cancer cells in blood cancers such as multiple myeloma. It generates revenue from clinical testing and from biopharma MRD services and milestones. clonoSEQ test volume grew 46% to 39,587 tests in Q3 2026. The test is supported by new NCCN and International Myeloma Working Group frameworks that emphasize MRD assessment.

The Immune Medicine segment partners with biopharmaceutical companies on drug discovery and development, including target discovery agreements and a past collaboration with Genentech. It also pursues immune-driven therapeutics and diagnostics in cancer and autoimmune disease, and the company is undertaking a process to separate this business.

Adaptive also consolidates Digital Biotechnologies, Inc., which has noncontrolling interests. The company recently refinanced its revenue interest liability with convertible senior notes. Updated

Latest Activity

ADPTAdaptive Biotechnologies
Q3 2026
EPS
$0.02
est -$0.10+$0.12
Revenue
$84M
est $72M+17.2%

First profitable quarter after years of losses, and it arrived earlier than management guided. clonoSEQ tests delivered rose 46% to 39,587, lifting full-year MRD revenue guidance.

Quarterly EPS — reported vs estimate

ADPT Coverage

Frequently Asked Questions

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies is a commercial-stage biotechnology company that decodes the genetics of the adaptive immune system to diagnose, monitor and treat disease. Its proprietary immune medicine platform sequences and interprets T-cell and B-cell receptor repertoires at scale.

What is the ADPT stock price target?

The Wall Street consensus 12-month price target for ADPT is $32.57.